

Frank T Peters

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8115374/publications.pdf>

Version: 2024-02-01

66
papers

4,168
citations

126907
33
h-index

110387
64
g-index

67
all docs

67
docs citations

67
times ranked

2874
citing authors

#	ARTICLE	IF	CITATIONS
1	Analytical techniques for the detection of novel psychoactive substances and their metabolites. , 2022, , 225-244.		0
2	Liquid Chromatography High-Resolution Mass Spectrometry in Forensic Toxicology: What are the Specifics of Method Development, Validation and Quality Assurance for Comprehensive Screening Approaches?. Current Pharmaceutical Design, 2022, 28, 1230-1244.	1.9	10
3	Principles of Forensic Toxicology, 5th edition (2020). Journal of Analytical Toxicology, 2021, 45, e6-e7.	2.8	1
4	HPLC-MS identification of acid degradation products of dolutegravir. Journal of Pharmaceutical and Biomedical Analysis, 2021, 197, 113954.	2.8	3
5	Antemortem and postmortem influences on drug concentrations and metabolite patterns in postmortem specimens. Wiley Interdisciplinary Reviews Forensic Science, 2019, 1, .	2.1	13
6	Liquid chromatography-mass spectrometry-based determination of ergocristine, ergocryptine, ergotamine, ergovaline, hypoglycin A, lolitrem B, methylene cyclopropyl acetic acid carnitine, N-acetyllooline, N-formyllooline, paxilline, and peramine in equine hair. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1117, 127-135.	2.3	8
7	Comparative study on the metabolism of the ergot alkaloids ergocristine, ergocryptine, ergotamine, and ergovaline in equine and human S9 fractions and equine liver preparations. Xenobiotica, 2019, 49, 1149-1157.	1.1	3
8	Development and validation of an ultrahigh performance liquid chromatography-high resolution tandem mass spectrometry quantification method for hypoglycin A and methylene cyclopropyl acetic acid carnitine in horse serum in cases of atypical myopathy. Drug Testing and Analysis, 2018, 10, 814-820.	2.6	5
9	Systematic investigations of novel validity parameters in urine drug testing and prevalence of urine adulteration in a two-year cohort. Drug Testing and Analysis, 2018, 10, 1536-1542.	2.6	13
10	Development and validation of an ultrahigh performance liquid chromatography-high resolution tandem mass spectrometry assay for nine toxic alkaloids from endophyte-infected pasture grasses in horse serum. Journal of Chromatography A, 2018, 1560, 35-44.	3.7	11
11	Recent advances of liquid chromatography-high resolution tandem mass spectrometry in clinical and forensic toxicology - An update. Clinical Biochemistry, 2016, 49, 1051-1071.	1.9	103
12	Search for fungi-specific metabolites of four model drugs in postmortem blood as potential indicators of postmortem fungal metabolism. Forensic Science International, 2016, 262, 173-178.	2.2	12
13	Studies on drug metabolism by fungi colonizing decomposing human cadavers. Part II: biotransformation of five model drugs by fungi isolated from postmortem material. Drug Testing and Analysis, 2015, 7, 265-279.	2.6	10
14	Recent developments in urinalysis of metabolites of new psychoactive substances using LC-MS. Bioanalysis, 2014, 6, 2083-2107.	1.5	43
15	Development and validation of a liquid chromatography-tandem mass spectrometry (LC-MS/MS) procedure for screening of urine specimens for 100 analytes relevant in drug-facilitated crime (DFC). Analytical and Bioanalytical Chemistry, 2014, 406, 4411-4424.	3.7	39
16	Analytical Techniques for the Detection of Novel Psychoactive Substances and Their Metabolites. , 2013, , 131-157.		5
17	Studies on drug metabolism by fungi colonizing decomposing human cadavers. Part I: DNA sequence-based identification of fungi isolated from postmortem material. Analytical and Bioanalytical Chemistry, 2013, 405, 8443-8450.	3.7	11
18	Analytical Toxicology of Emerging Drugs of Abuse - An Update. Therapeutic Drug Monitoring, 2012, 34, 615-621.	2.0	32

#	ARTICLE	IF	CITATIONS
19	Systematic toxicological analysis using liquid chromatography-mass spectrometry: techniques and inter-instrument reproducibility of mass spectra/Systematisch-toxikologische Analyse mittels Hochleistungsflüssigchromatographie-Massenspektrometrie: Techniken und Reproduzierbarkeit von Massenspektren zwischen Instrumenten. <i>Laboratoriums Medizin</i> , 2012, 36, .	0.6	1
20	Engineering of Human CYP3A Enzymes by Combination of Activating Polymorphic Variants. <i>Applied Biochemistry and Biotechnology</i> , 2012, 168, 785-796.	2.9	13
21	Studies on the metabolism of five model drugs by fungi colonizing cadavers using LC-ESI-MS/MS and GC-MS analysis. <i>Analytical and Bioanalytical Chemistry</i> , 2012, 404, 1339-1359.	3.7	9
22	Aspects of matrix effects in applications of liquid chromatography-mass spectrometry to forensic and clinical toxicology-a review. <i>Analytical and Bioanalytical Chemistry</i> , 2012, 403, 2155-2172.	3.7	138
23	Towards a universal LC-MS screening procedure - can an LIT LC-MS ⁿ screening approach and reference library be used on a quadrupole-LIT hybrid instrument?. <i>Journal of Mass Spectrometry</i> , 2012, 47, 66-71.	1.6	31
24	<i>In vitro</i> approaches to studying the metabolism of new psychoactive compounds. <i>Drug Testing and Analysis</i> , 2011, 3, 483-495.	2.6	62
25	Practical aspects concerning validation and quality control for forensic and clinical bioanalytical quantitative methods. <i>Accreditation and Quality Assurance</i> , 2011, 16, 279-292.	0.8	98
26	Forensic toxicology. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 400, 7-8.	3.7	4
27	Acute poisoning involving the pyrrolidinophenone-type designer drug 4-ethyl-2-methyl-alpha-pyrrolidinohexanophenone (MPHP). <i>Forensic Science International</i> , 2011, 208, e20-e25.	2.2	36
28	Convenient Gram-Scale Metabolite Synthesis by Engineered Fission Yeast Strains Expressing Functional Human P450 Systems. <i>Applied Biochemistry and Biotechnology</i> , 2011, 163, 965-980.	2.9	62
29	Recent advances of liquid chromatography-(tandem) mass spectrometry in clinical and forensic toxicology. <i>Clinical Biochemistry</i> , 2011, 44, 54-65.	1.9	171
30	Whole-cell biotransformation assay for investigation of the human drug metabolizing enzyme CYP3A7. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2011, 1814, 161-167.	2.3	21
31	Analytical Toxicology of Emerging Drugs of Abuse. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 532-539.	2.0	51
32	Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 397, 1225-1233.	3.7	246
33	Fast and simple procedure for liquid-liquid extraction of 136 analytes from different drug classes for development of a liquid chromatographic-tandem mass spectrometric quantification method in human blood plasma. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 397, 2303-2314.	3.7	67
34	Production of human phase 1 and 2 metabolites by whole-cell biotransformation with recombinant microbes. <i>Bioanalysis</i> , 2010, 2, 1277-1290.	1.5	41
35	CYP21-catalyzed production of the long-term urinary metandienone metabolite 17β-hydroxymethyl-17β-methyl-18-norandrost-1,4,13-trien-3-one: a contribution to the fight against doping. <i>Biological Chemistry</i> , 2010, 391, 119-27.	2.5	32
36	Automated Mass Spectral Deconvolution and Identification System for GC-MS Screening for Drugs, Poisons, and Metabolites in Urine. <i>Clinical Chemistry</i> , 2010, 56, 575-584.	3.2	120

#	ARTICLE	IF	CITATIONS
37	Biotechnological Synthesis of the Designer Drug Metabolite 4'-Hydroxymethyl- α -pyrrolidino-hexanophenone in Fission Yeast Heterologously Expressing Human Cytochrome P450 2D6—A Versatile Alternative to Multistep Chemical Synthesis. <i>Journal of Analytical Toxicology</i> , 2009, 33, 190-197.	2.8	25
38	The Role of Human Hepatic Cytochrome P450 Isozymes in the Metabolism of Racemic 3,4-Methylenedioxyethylamphetamine and Its Single Enantiomers. <i>Drug Metabolism and Disposition</i> , 2009, 37, 1152-1156.	3.3	23
39	Human CYP4Z1 catalyzes the in-chain hydroxylation of lauric acid and myristic acid. <i>Biological Chemistry</i> , 2009, 390, 313-317.	2.5	49
40	Biotechnological synthesis of drug metabolites using human cytochrome P450 isozymes heterologously expressed in fission yeast. <i>Bioanalysis</i> , 2009, 1, 821-830.	1.5	15
41	Investigations on the cytochrome P450 (CYP) isoenzymes involved in the metabolism of the designer drugs N-(1-phenyl cyclohexyl)-2-ethoxyethanamine and N-(1-phenylcyclohexyl)-2-methoxyethanamine. <i>Biochemical Pharmacology</i> , 2009, 77, 444-450.	4.4	15
42	Stereoselective differences in the cytochrome P450-dependent dealkylation and demethylenation of N-methyl-benzodioxolyl-butanamine (MBDB, Eden) enantiomers. <i>Biochemical Pharmacology</i> , 2009, 77, 1725-1734.	4.4	25
43	New designer drug α -pyrrolidinovalerophenone (PVP): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. <i>Journal of Mass Spectrometry</i> , 2009, 44, 952-964.	1.6	83
44	Use of fission yeast heterologously expressing human cytochrome P450 2B6 in biotechnological synthesis of the designer drug metabolite N-(1-phenylcyclohexyl)-2-hydroxyethanamine. <i>Forensic Science International</i> , 2009, 184, 69-73.	2.2	23
45	Investigations on the human hepatic cytochrome P450 isozymes involved in the metabolism of 3,4-methylenedioxy-amphetamine (MDA) and benzodioxolyl-butanamine (BDB) enantiomers. <i>Toxicology Letters</i> , 2009, 190, 54-60.	0.8	16
46	New designer drugs N-(1-phenylcyclohexyl)-2-ethoxyethanamine (PCEEA) and N-(1-phenylcyclohexyl)-2-methoxyethanamine (PCMEA): Studies on their metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. <i>Journal of Mass Spectrometry</i> , 2008, 43, 305-316.	1.6	29
47	Identification of Cytochrome P450 Enzymes Involved in the Metabolism of the Designer Drugs N-(1-Phenylcyclohexyl)-3-ethoxypropanamine and N-(1-Phenylcyclohexyl)-3-methoxypropanamine. <i>Chemical Research in Toxicology</i> , 2008, 21, 1949-1955.	3.3	13
48	Identification of Cytochrome P450 Enzymes Involved in the Metabolism of the New Designer Drug 4-Methyl- α -pyrrolidinobutyrophenone. <i>Drug Metabolism and Disposition</i> , 2008, 36, 163-168.	3.3	19
49	The Role of Human Hepatic Cytochrome P450 Isozymes in the Metabolism of Racemic 3,4-Methylenedioxy-Methamphetamine and Its Enantiomers. <i>Drug Metabolism and Disposition</i> , 2008, 36, 2345-2354.	3.3	88
50	Systematic Comparison of Bias and Precision Data Obtained with Multiple-Point and One-Point Calibration in Six Validated Multianalyte Assays for Quantification of Drugs in Human Plasma. <i>Analytical Chemistry</i> , 2007, 79, 4967-4976.	6.5	46
51	Detection and validated quantification of nine herbal phenalkylamines and methcathinone in human blood plasma by LC-MS/MS with electrospray ionization. <i>Journal of Mass Spectrometry</i> , 2007, 42, 150-160.	1.6	77
52	Detection and validated quantification of toxic alkaloids in human blood plasma—comparison of LC-APCI-MS with LC-ESI-MS/MS. <i>Journal of Mass Spectrometry</i> , 2007, 42, 621-633.	1.6	89
53	Validation of new methods. <i>Forensic Science International</i> , 2007, 165, 216-224.	2.2	1,093
54	Biotechnological synthesis of drug metabolites using human cytochrome P450 2D6 heterologously expressed in fission yeast exemplified for the designer drug metabolite 4-Methyl- α -pyrrolidinobutyrophenone. <i>Biochemical Pharmacology</i> , 2007, 74, 511-520.	4.4	43

#	ARTICLE	IF	CITATIONS
55	Stability of analytes in biosamples—“an important issue in clinical and forensic toxicology?”. Analytical and Bioanalytical Chemistry, 2007, 388, 1505-1519.	3.7	75
56	Fast, Simple, and Validated Gas Chromatographic-Mass Spectrometric Assay for Quantification of Drugs Relevant to Diagnosis of Brain Death in Human Blood Plasma Samples. Therapeutic Drug Monitoring, 2005, 27, 334-344.	2.0	37
57	Studies on the metabolism and toxicological detection of the new designer drug 4- ϵ -methyl- β -pyrrolidinobutyrophenone (MPBP) in rat urine using gas chromatography—“mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 824, 81-91.	2.3	49
58	Studies on the metabolism and toxicological detection of the designer drug 4-methylthioamphetamine (4-MTA) in human urine using gas chromatography—“mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 824, 123-131.	2.3	43
59	Screening for and validated quantification of phenethylamine-type designer drugs and mescaline in human blood plasma by gas chromatography/mass spectrometry. Journal of Mass Spectrometry, 2005, 40, 785-795.	1.6	58
60	Drug Testing in Blood: Validated Negative-Ion Chemical Ionization Gas Chromatographic—“Mass Spectrometric Assay for Enantioselective Measurement of the Designer Drugs MDEA, MDMA, and MDA and Its Application to Samples from a Controlled Study with MDMA. Clinical Chemistry, 2005, 51, 1811-1822.	3.2	49
61	Screening for and validated quantification of amphetamines and of amphetamine- and piperazine-derived designer drugs in human blood plasma by gas chromatography/mass spectrometry. Journal of Mass Spectrometry, 2003, 38, 659-676.	1.6	162
62	New designer drug 4- ϵ -methyl- β -pyrrolidinoheptanophenone: studies on its metabolism and toxicological detection in urine using gas chromatography—“mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 789, 79-91.	2.3	57
63	Bioanalytical method validation and its implications for forensic and clinical toxicology - A review. Accreditation and Quality Assurance, 2002, 7, 441-449.	0.8	198
64	Studies on the metabolism and toxicological detection of the new designer drug 4- ϵ -methyl- β -pyrrolidinopropiophenone in urine using gas chromatography—“mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 773, 25-33.	2.3	54
65	Drug Testing in Blood: Validated Negative-Ion Chemical Ionization Gas Chromatographic—“Mass Spectrometric Assay for Determination of Amphetamine and Methamphetamine Enantiomers and Its Application to Toxicology Cases. Clinical Chemistry, 2002, 48, 1472-1485.	3.2	72
66	Drug testing in blood: validated negative-ion chemical ionization gas chromatographic-mass spectrometric assay for determination of amphetamine and methamphetamine enantiomers and its application to toxicology cases. Clinical Chemistry, 2002, 48, 1472-85.	3.2	17